| Name | Relationship | Address | Signature | Signature date | CIK |
|---|---|---|---|---|---|
| Hunt Anthony | Director | C/O REPLIGEN CORPORATION, 41 SEYON ST., BLDG 1, STE 100, WALTHAM | /s/ Jennifer Carmichael (Attorney in Fact) | 11 Sep 2025 | 0001606030 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | RGEN | Common Stock | Options Exercise | $677,400 | +20,000 | +18% | $33.87 | 129,854 | 10 Sep 2025 | Direct | |
| transaction | RGEN | Common Stock | Sale | $11,169 | -96 | -0.07% | $116.34 | 129,758 | 10 Sep 2025 | Direct | F1 |
| transaction | RGEN | Common Stock | Sale | $131,099 | -1,108 | -0.85% | $118.32 | 128,650 | 10 Sep 2025 | Direct | F1, F2 |
| transaction | RGEN | Common Stock | Sale | $390,266 | -3,262 | -2.5% | $119.64 | 125,388 | 10 Sep 2025 | Direct | F1, F3 |
| transaction | RGEN | Common Stock | Sale | $1,788,668 | -14,882 | -12% | $120.19 | 110,506 | 10 Sep 2025 | Direct | F1, F4 |
| transaction | RGEN | Common Stock | Sale | $920,849 | -7,584 | -6.9% | $121.42 | 102,922 | 10 Sep 2025 | Direct | F1, F5 |
| transaction | RGEN | Common Stock | Sale | $266,339 | -2,179 | -2.1% | $122.23 | 100,743 | 10 Sep 2025 | Direct | F1, F6 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | RGEN | Stock Option (Right to Buy) | Options Exercise | $0 | -20,000 | -9.9% | $0.000000 | 182,344 | 10 Sep 2025 | Common Stock | 20,000 | $33.87 | Direct | F7 |
| Id | Content |
|---|---|
| F1 | Sale of common stock was effected pursuant to a 10(b)5-1 trading plan adopted on December 9, 2024. |
| F2 | $118.32 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $117.80 to $118.76, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. |
| F3 | $119.64 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $118.83 to $119.83, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. |
| F4 | $120.19 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $119.85 to $120.80, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. |
| F5 | $121.42 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $120.86 to $121.86, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. |
| F6 | $122.23 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $121.92 to $122.61, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. |
| F7 | 207,344 of the shares underlying this option have vested. The remaining shares vest as follows: 28,777 shares on March 1, 2026, and 28,778 shares on March 1, 2027. |